067630 — HLB Life Science Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩1tn
- KR₩1tn
- KR₩98bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 114,019 | 91,797 | 53,494 | 99,591 | 97,990 |
Cost of Revenue | |||||
Gross Profit | 7,607 | 2,326 | -5,537 | -3,046 | -749 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 151,624 | 132,352 | 85,760 | 134,514 | 163,499 |
Operating Profit | -37,605 | -40,555 | -32,265 | -34,922 | -65,508 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6,561 | -56,490 | -53,624 | -60,839 | -6,503 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7,563 | -55,836 | -49,292 | -54,360 | -5,913 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -7,605 | -55,797 | -49,152 | -54,277 | -5,983 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -7,605 | -55,797 | -49,152 | -54,277 | -5,983 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 146 | -343 | -395 | -451 | 194 |
Dividends per Share |